Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statements Detail (Tables)

v2.4.1.9
Condensed Consolidated Financial Statements Detail (Tables)
 3 Months Ended
Mar. 31, 2015
Condensed Consolidated Financial Statements Detail [Abstract]  
Outstanding securities considered anti-dilutive
The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share (in thousands):

    March 31,  
   
2015
    
2014
  
Common stock options and restricted stock units
    
8,756
      
5,732
  
Warrants for common stock
    
20,690
      
1,910
  
Total
    
29,446
      
7,642
  
Reconciliation of the numerators and denominators of the basic and diluted net loss per share of common stock
For the three months ended March 31, 2015 and 2014, the following is a reconciliation of the numerators and denominators of the basic and diluted net loss per share of common stock (in thousands):

   
Three Months Ended March 31,
  
   
2015
    
2014
  
Numerator
  
   
 
Net loss
  
   
 
Basic
  
$
(21,718
)
  
$
(4,687
)
Adjustment for revaluation of contingent warrant liabilities
    
-
      
(19,534
)
Diluted
  
$
(21,718
)
  
$
(24,221
)
                 
Denominator
                
Weighted average shares outstanding used for basic net loss per share
    
116,193
      
106,158
  
Effect of dilutive warrants
    
-
      
9,366
  
Weighted average shares outstanding and dilutive securities used for diluted net loss per share
    
116,193
      
115,524
  
Accrued liabilities
Accrued and other liabilities consisted of the following at March 31, 2015 and December 31, 2014 (in thousands):

   
March 31,
 2015
    
December 31,
 2014
  
Accrued payroll and other benefits
  
$
2,578
    
$
3,061
  
Accrued management incentive compensation
    
1,149
      
4,295
  
Accrued clinical trial costs
    
1,079
      
1,424
  
Other
    
1,186
      
1,112
  
Total
  
$
5,992
    
$
9,892